Next Article in Journal
Implementation of Novel Quality Assurance Program for Hepatitis C Viral Load Point of Care Testing
Previous Article in Journal
Comparing Current and Next-Generation Humanized Mouse Models for Advancing HIV and HIV/Mtb Co-Infection Studies
Previous Article in Special Issue
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 14
Issue 9
10.3390/v14091928
Review Report
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses

Viruses 2022, 14(9), 1928; https://0-doi-org.brum.beds.ac.uk/10.3390/v14091928
by Abdelhakim Ahmed-Belkacem 1, Rabah Redjoul 2, Rozenn Brillet 1, Nazim Ahnou 1, Mathieu Leclerc 1,2, Dennis Salomón López-Molina 1, Alexandre Soulier 3, Aurélie Gourgeon 3, Christophe Rodriguez 1,3, Sébastien Maury 1,2, Jean-Michel Pawlotsky 1,3 and Slim Fourati 1,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3:
Michael G. Ison
Viruses 2022, 14(9), 1928; https://0-doi-org.brum.beds.ac.uk/10.3390/v14091928
Submission received: 31 March 2022 / Revised: 22 August 2022 / Accepted: 25 August 2022 / Published: 30 August 2022
(This article belongs to the Special Issue SARS-CoV-2 Research in France)

Round 1

Reviewer 1 Report

Summary: 

The COVID-19 pandemic continues despite the availability and distribution of multiple types of vaccine. Particularly vulnerable populations, such as those with immune deficiencies are vulnerable to infection and severe disease. Vaccine take in vulnerable populations is an important research concern. This study uses neutralization and binding titers of clinical sera to highlight the difficulty in immunizing immune-suppressed individuals with a standard prime/boost strategy. After a third dose, binding and neutralizing antibody titers are increased. Additionally, the researchers assert correlation between binding and neutralizing antibodies in support of using antigen based assays in the clinic.

General Comments:

  1. Use of the term variant of origin is not standard usage and there are similar terms used by the CDC and WHO. Usage of ancestral, prototype, or wild-type may be less confusing and more accurate.

Specific Comments:

Line 131: Elaborate your method for testing neutralization. How much SARS-CoV-2 was added to the diluted patient sera? Did you use overall levels of fluorescence or the number of infected cells to determine the neutralization endpoint?

Line 149-151: This format text should be removed in the final manuscript.

 

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The papers deals with a question that is now quite old. Most immunosuppressed patients have received a fourth vaccine dose, and are approaching the fifth. Furthermore, nAb titers were measured against Beta and Delta, while nowadays we have Omicron

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

Overall, the authors present the data on 3rd booster dose for HSCT patients. There is no data relevant to omicron which is a significant weakness and reduces the utility of the data.  

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 3 Report

I have no further comments to strengthen the paper

Author Response

We thank the reviewers and editor for their positive comments. 

We modified the text of the manuscript according to the editor's suggestion

Back to TopTop